Dr. Patrick Amstutz is the co-founder and Chief Executive Officer of Molecular Partners AG, a clinical-stage biopharmaceutical company based in Zürich, Switzerland. Since co-founding the company in 2004, he has played a pivotal role in developing DARPins, a novel class of engineered protein therapeutics, and has led the company through significant milestones in oncology, ophthalmology, and infectious diseases. Under his leadership, Molecular Partners has focused on advancing precision treatments, including T-cell engagers and targeted radiotherapies. Dr. Amstutz holds a Master of Science from ETH Zurich and a Ph.D. in molecular biology from the University of Zurich. In 2022, he was elected President of the Board of Directors of the Swiss Biotech Association, reflecting his influence in the global biotech community.